Generation Bio Announces CEO Transition
Generation Bio (Nasdaq: GBIO) announced a leadership transition effective October 31, 2025. Geoff McDonough, MD will step down as Chief Executive Officer and President and become Chair of the Board. The Board appointed Yalonda Howze, JD, currently Chief Legal Officer since April 2023, as Interim CEO and President. Jason Rhodes will step down as Board Chair and remain a director. The company described the change as a transition and expressed confidence in Howze’s interim leadership.
Generation Bio (Nasdaq: GBIO) ha annunciato una successione della leadership efficace 31 ottobre 2025. Geoff McDonough, MD, lascerà l'incarico di Amministratore Delegato e Presidente e diventerà Presidente del Consiglio di Amministrazione. Il Consiglio ha nominato Yalonda Howze, JD, attualmente Chief Legal Officer dal aprile 2023, come Amministratore Delegato e Presidente ad interim. Jason Rhodes si dimetterà dalla carica di Presidente del Consiglio e rimarrà direttore. L'azienda ha descritto la modifica come una transizione e ha espresso fiducia nella leadership ad interim di Howze.
Generation Bio (Nasdaq: GBIO) anunció una transición de liderazgo con efecto a partir del 31 de octubre de 2025. Geoff McDonough, MD dejará su cargo como Director Ejecutivo y Presidente y pasará a Presidente de la Junta. La Junta designó a Yalonda Howze, JD, actualmente Directora Legal desde abril de 2023, como CEO y Presidente interino. Jason Rhodes dejará de ser Presidente de la Junta y permanecerá como director. la empresa describió el cambio como una transición y expresó confianza en el liderazgo interino de Howze.
Generation Bio (Nasdaq: GBIO)는 2025년 10월 31일부로 리더십 이양을 발표했습니다. Geoff McDonough, MD는 최고경영자 겸 사장직에서 물러나 이사회 의장으로 취임합니다. 이사회는 2023년 4월부터 최고법무책임자(CLO)였던 Yalonda Howze, JD를 임시 CEO 겸 사장으로 임명했습니다. Jason Rhodes는 이사회 의장직에서 물러나 이사로 남을 것입니다. 회사는 이 변화를 전환으로 설명했고 Howze의 임시 리더십에 대해 신뢰를 표했습니다.
Generation Bio (Nasdaq: GBIO) a annoncé une transition de leadership effective le 31 octobre 2025. Geoff McDonough, MD, quittera ses fonctions de directeur général et de président et deviendra Président du conseil d'administration. Le conseil a nommé Yalonda Howze, JD, actuellement Chief Legal Officer depuis avril 2023, comme PDG et président par intérim. Jason Rhodes cédera sa fonction de Président du conseil et restera administrateur. L'entreprise a décrit ce changement comme une transition et a exprimé sa confiance dans le leadership intérim de Howze.
Generation Bio (Nasdaq: GBIO) kündigte eine Führungübergabe mit Wirkung zum 31. Oktober 2025 an. Geoff McDonough, MD, wird als Chief Executive Officer und President zurücktreten und Vorsitzender des Vorstands werden. Der Vorstand ernannte Yalonda Howze, JD, derzeitige Chief Legal Officer seit April 2023, als interimistischen CEO und Präsidenten des Unternehmens. Jason Rhodes wird als Vorsitzender des Vorstands zurücktreten und Direktor bleiben. Das Unternehmen bezeichnete die Änderung als Übergang und bekundete Vertrauen in Howzes interimistische Führung.
Generation Bio (ناسداك: GBIO) أعلنت عن انتقال قيادي ساري المفعول اعتباراً من 31 أكتوبر 2025. سيتنحّى جورف ماكدونوغ، MD عن منصب الرئيس التنفيذي والرئيس وسيصبح رئيس مجلس الإدارة. عيّن المجلس يالوندا هوذر، JD، التي تشغل حالياً منصب المدير القانوني الأعلى منذ أبريل 2023، كـ الرئيس التنفيذي ورئيس مؤقت للمجلس. سيتنحى جايسن رودز عن رئاسة المجلس وسيبقى عضواً في المجلس. وصفت الشركة التغيير بأنه انتقال وأعربت عن ثقتها في القيادة المؤقتة لهوز.
Generation Bio (纳斯达克：GBIO) 宣布了一项领导层过渡，生效日期为2025年10月31日。Geoff McDonough, MD 将辞去首席执行官兼总裁职务，改任董事会主席。董事会任命 Yalonda Howze, JD，自2023年4月起担任首席法务官，为临时首席执行官兼总裁。Jason Rhodes 将辞去董事会主席职务，保留为董事。公司将此次变动描述为过渡，并对 Howze 的临时领导表示信心。
- Internal promotion: Chief Legal Officer named Interim CEO
- Geoff McDonough retains oversight as Board Chair
- Board continuity: Jason Rhodes remains a director
- Leadership change introduces transition risk for near-term strategy
- Interim CEO status may create short-term uncertainty for investors
• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors
• Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President
CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company’s Board of Directors. The Board has appointed Yalonda Howze, JD, as Interim Chief Executive Officer and President. Ms. Howze has served as the Company’s Chief Legal Officer since joining in April 2023. Jason Rhodes will step down as Chair of the Board and will remain a Board Director. These changes will be effective October 31, 2025.
“Geoff has been instrumental in building Generation Bio, and we look forward to his leadership as Board Chair.” said Jason Rhodes, former Board Chair of Generation Bio. “We have the highest confidence in Yalonda’s ability to lead Generation Bio in her new role during this time of transition for the company.”
About Generation Bio
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.
For more information, please visit www.generationbio.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the company, including statements about the company’s leadership transition, the company’s strategic alternatives process, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties as to the company’s ability to successfully pursue a strategic alternative transaction on attractive terms, or at all; whether the chief executive officer transition will be successful; as well as the other risks and uncertainties set forth in the “Risk Factors” section of the company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date on which they were made.
Investors and Media Contact
Kevin Conway
Generation Bio
investors@generationbio.com
(857) 371-4721
FAQ
Who will lead Generation Bio (GBIO) after October 31, 2025?
What role will Geoff McDonough have at Generation Bio (GBIO) after October 31, 2025?
When did Yalonda Howze join Generation Bio and what was her role before becoming Interim CEO?
Will Jason Rhodes remain involved with Generation Bio (GBIO) after stepping down as Board Chair?
How might the October 31, 2025 leadership changes affect GBIO shareholders?
